SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person		son [*]	2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Snanmugar</u>	anmugam Muthusamy			X	Director	10% Owner			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/15/2024	X	Officer (give title below)	Other (specify below)			
C/O ANI PHA	RMACEUTICAL	S, INC.			AD OF R&D, COO-NOVITIUM OPS				
210 MAIN STREET WEST			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applic Line)				
(Street)				X Form filed by One Reporting Person					
BAUDETTE	MN	56623			Form filed by More that Person	n One Reporting			
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication						
			X Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership 2A. Deemed 1. Title of Security (Instr. 3) 2. Transaction 5. Amount of 7. Nature Date (Month/Day/Year) Execution Date, Transaction Securities Beneficially Form: Direct of Indirect if anv Code (Instr. (D) or Indirect Beneficial (Month/Day/Year) 8) Owned Following Reported (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) Price Code v Amount (Instr. 3 and 4) Common Stock 68,652 D Held by **S**⁽¹⁾ Common Stock 04/15/2024 7,414 D \$66.33(2) 825,206 I Esjay LLC⁽³⁾ Held by Common Stock 04/16/2024 **S**⁽¹⁾ 5,834 \$66.2(4) 819,372 Ι D Esjay LLC⁽³⁾ Held by **S**⁽¹⁾ **\$65.4**⁽⁵⁾ Common Stock 04/17/2024 9,520 D 809,852 I Esjay LLC⁽³⁾ Held by SS 5,000 Common Stock I Pharma LLC⁽⁶⁾ Tabla II Darivative Securities Acquired Disposed of or Bonoficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Amount of Securities Security Jnderlying (Instr. 5) Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

2. The shares were sold in multiple trades at prices ranging from \$65.65 to \$67.27. The price reported above reflects the weighted average sales price.

3. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

4. The shares were sold in multiple trades at prices ranging from \$66.01 to \$66.58. The price reported above reflects the weighted average sales price.

5. The shares were sold in multiple trades at prices ranging from \$65.04 to \$66.06. The price reported above reflects the weighted average sales price.

6. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Remarks:

/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith W. Cook

04/17/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.